Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,190.00
Ask: 12,194.00
Change: 128.00 (1.06%)
Spread: 4.00 (0.033%)
Open: 12,194.00
High: 12,266.00
Low: 12,054.00
Prev. Close: 12,062.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Car industry: Better be selective

Wed, 08th Jul 2020 12:28

* European shares slip

* Wall Street rose overnight

* UK's Sunak to map out next moves in recovery plan
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts Joice Alves (joice.alves@thomsonreuters.com) and
Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

CAR INDUSTRY: BETTER BE SELECTIVE (1100 GMT)

The car industry is seen recovering in the second half of 2020 as lockdowns easing in Europe
continues, but will investors be willing to buy auto shares?

In terms of sales and production, barring a post-vacation second wave of infections in
Europe, the industry is expected to suffer from some seasonality impact in Q3 2020, before
picking up strongly in Q4.

But auto share prices could drop further in UBS' worst-case scenario, which includes a 17%
drop in global sales in 2020, as "cascading effects" might step in, such as recapitalisation
needs.

In the Swiss bank's base scenario, with a 9% drop in global sales and production, the STOXX
auto index tracked the drop in earnings, which the bank "sharply" reduced.

UBS suggests being selective and "buy names with a strong balance sheet and cash generation,
an above-average degree of cost flexibility" and which can be winners in the transition to
electric cars, such as Volkswagen, Hella, Michelin.

(Stefano Rebaudo)

*****

GOODBYE MR BOND (0950)

Much has been written on how the 60/40 equity/bond portfolio split -- beloved of fund
managers of a certain vintage -- is losing its mojo.

The blame falls squarely on the G7 government bond, which provides neither income in good
times or safety when things go sour.

Some reckon a investment-grade corporate bonds are in a position to assume the safe-haven
role once played by government debt, given they are now backstopped by central bank purchases.
But a recent JPMorgan note advised ditching the 60/40 altogether in favour of other number
combos.

One suggestion they make is to cut down on bond allocations and go 80/20. Another is a
20/40/40 mix of bonds, hybrids and equities. (As the name suggests, hybrids are a cross between
stocks and bonds and include things like preferred shares or convertible debt)

Or forget bonds altogether and go for a 60/40 hybrid/equity portfolio. (Returns would be a
respectable 5% a year, JPM estimates).

Finally, what about 80/20 but with the bond component comprised half-and-half of junk and
top-grade debt.

As for returns on all these options, they range 4%-5% a year. That doesn't sound like much
more than the 3.5% JPM expects from the traditional 60/40, but as it points out: it adds up over
the years.

(Sujata Rao)

*****

SUNAK'S TIME TO IMPRESS (0909 GMT)

All eyes will be on UK's Sunak, who will unveil later today (around 1130 GMT) his plans to
revamp the economy as he tries to prevent the UK to fall into an unemployment crisis.

What shall we expect in terms of stocks reaction?

The quick answer is not much, as there has been a fair amount of reports anticipating some
of his planned moves, analysts suggest.

But fresh stimulus can always "have a positive impact" on the FTSE, says Ipek Ozkardeskaya,
senior analyst at Swissquote Bank.

Here're a few details on Sunak's plans:

- a 2 billion-pound fund to create six-month work-placement jobs for unemployed 16-24
year-olds.

- 3 billion pounds to improve the energy efficiency of homes and public buildings.

- he is reportedly considering a stamp duty holiday and giving away vouchers to boost
spending in hospitality businesses.

Some analysts' comments:

Deutsche Bank - "Our UK economists’ base case is that Sunak will broadly stick to the
mandate set out by PM Johnson last week, possibly topping up the package by another 0.2% of GDP,
focusing particularly on apprenticeship schemes, and modest wage subsidies to get furloughed
employees back into work".

UniCredit - "We certainly do not expect the government to extend the jobs retention scheme;
indeed, while the government accepts the likelihood of a big increase in job losses when the
scheme ends, it appears to have made a judgement that many of these jobs would ultimately be
lost anyway, and that it's better to support a reallocation of these workers to growth sectors".

LCG Research - "High hopes for more infrastructure spending, business grants or tax cuts
could quickly disappear if the focus remains on keeping jobs".

(Joice Alves)

*****

OPENING SNAPSHOT: WAIT AND SEE MOOD (0740 GMT)

European stocks are in negative territory as a surge in coronavirus cases in the U.S. has
clouded hopes for a swift economic recovery.

Investors are in a wait and see mood ahead of the upcoming earnings season, and next week's
ECB meeting and EU summit where leaders will discuss the recovery fund.

Britain's finance minister will announce later today his next moves to prevent a wave of job
cuts from snowballing into an unemployment crisis.

The STOXX 600 index is down 0.3% with banks leading losses down 1.2%, while oil and
gas shares drop 0.5% as oil prices dipped on renewed oversupply fears after data showed a build
in U.S. crude stockpiles.

Shares in Electrolux are among the best performers of the STOXX 600, up 6%, after
the company reported a smaller than expected loss. Victrex stocks, touched a
three-month lows, and are now down almost 4% after the company's trading update.

(Stefano Rebaudo)

*****

ON THE RADAR: INSURERS, BOOHOO, ASTRAZENECA, MERCK (0650 GMT)

European stocks are set for a session in the red, with investors in wait and see mode ahead
of the upcoming earnings session, while they are trying to assess if rising cases in the U.S.
will lead to more restrictive measures.

On the corporate front, commercial insurers are facing hefty claims from the coronavirus
crisis but are also seeing a steep rise in premiums – tempting companies and industry veterans
to raise capital, launch new businesses or expand into new lines. Lloyd's of London, insurers
Beazley, Hiscox and Lancashire are among those to raise equity.

AstraZeneca and Merck & Co said their blockbuster cancer treatment Lynparza
won approval in the European Union for treating patients with a form of pancreatic cancer.

Zalando will delist all products made by Britain's Boohoo following a
media report about dire working conditions in a English factory that supplied the popular brand.
Boohoo decided to launch an independent review of its supply chain in Britain.

Shares in Traton down 3.6% after the company announced management change.
Deutsche Post stocks up 1.3% in early trade after reporting a 16% rise
in second-quarter operating profit.

FirstGroup warned on its ability to continue as a going concern, after posting an
annual operating loss as passenger volumes plummeted due to the coronavirus crisis.

Electrolux said it will report a smaller loss for the second quarter of 2020 than
previously anticipated, with operating income estimated at about 100 million crown.

OMV Q2 output dropped 5% in wake of coronavirus pandemic.

Other headlines:

Diaceutics says sales for first half increased by 20%

Britain's Funding Circle to cut 85 U.S. jobs

Marlowe plc says FY adjusted profit before tax up 54%

Liontrust Asset Management says net inflows of £971 mln in 3 months ended 30 June 2020

Amigo Holdings appoints Glen Crawford as CEO

Italy's Stefanel draws 4 expressions of interest, expects more

(Stefano Rebaudo)

*****

MORNING CALL: NOT MUCH TO LOOK FORWARD TOO (0545 GMT)

European bourses seem poised to open in negative territory this morning with little to look
forward to after Asia and Wall Street failed to gain momentum and switched to 'wait-and-see'.

Futures for pan-European blue chips, the DAX and the FTSE were down 0.7%, 0.6% and 0.8%
respectively.

The resurgent coronavirus pandemic is keeping Wall Street in check while in Asia, the
bullishness surrounding Chinese shares failed to spread significantly across beyond the region.

Very little macro indicators or corporate events in Europe today to help markets find their
way.

Looking forward, investors will be eager to get into the Q2 earnings season to see for
themselves if the V-shaped recovery priced in the market is indeed on its way.

(Julien Ponthus)

*****

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.